HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Successful treatment of disseminated granuloma annulare with adalimumab.

Abstract
A 61-year-old female with a 4-year history of disseminated granuloma annulare was successfully treated with the antitumor necrosis factor (TNF)-alpha antibody, adalimumab. The patient had failed high potency topical glucocorticoids, hydroxychloroquine, and narrow-band ultraviolet light (UV)-B phototherapy. Anti-TNF-alpha therapy may be a therapeutic option in patients with disseminated granuloma annulare poorly controlled with conventional medications.
AuthorsDavid Rosmarin, Anne LaRaia, Scott Schlauder, Alice B Gottlieb
JournalJournal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 8 Issue 2 Pg. 169-71 (Feb 2009) ISSN: 1545-9616 [Print] United States
PMID19213233 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • Adalimumab
Topics
  • Adalimumab
  • Anti-Inflammatory Agents (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Biopsy
  • Female
  • Granuloma Annulare (drug therapy, immunology, pathology)
  • Histiocytes (pathology, ultrastructure)
  • Humans
  • Middle Aged
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: